Q3 2024 GeoVax Labs Inc Earnings Call Transcript

Nov 12, 2024 / 09:30 PM GMT

Transcript 8-K10-Q

Key Points

Positve

Geovax Labs Inc (GOVX) received a significant BARDA Project NextGen Award valued at almost $400 million, supporting a 10,000 patient comparative trial.
The company is advancing its vaccine candidate against monkeypox and smallpox, with production of the first CGMP clinical substance batch underway.
Geovax Labs Inc (GOVX) is progressing with its advanced MVA manufacturing process, which could enhance production efficiency.
The company is actively pursuing business partnerships and collaborations for worldwide development and commercialization.
Geovax Labs Inc (GOVX) reported increased revenues of $2.8 million for the third quarter, reflecting progress in its BARDA contract.

Negative

Geovax Labs Inc (GOVX) reported a net loss of $16.7 million for the first nine months of 2024, primarily driven by manufacturing activities and costs associated with the BARDA contract.
The company faces challenges in the competitive landscape, with potential development of more effective or easier-to-use products by competitors.
There is uncertainty regarding the timing of regulatory approvals and the ability to meet expedited pathways for its vaccine candidates.
Geovax Labs Inc (GOVX) has ongoing financial needs to support its clinical programs and development activities, requiring careful capital management.
The company is dependent on successful partnerships and collaborations to achieve its commercialization and distribution goals.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

GOVX.OQ - GeoVax Labs Inc
Q3 2024 GeoVax Labs Inc Earnings Call
Nov 12, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon and welcome everyone to the Geovax third quarter, 2024 corporate update call. My name is Michelle and I'll facilitate today's call with me are David dot Chairman CEO Mark Reynolds, Chief Financial Officer, Mark Newman phd, Chief Scientific Officer, Kelly mckee MD MP, Chief Medical Officer and John Sharkey phd, Vice President Business Development.

At this time, all participants are in listen-only mode. A question answer says you will follow the formal presentation as a reminder. This conference is being recorded at this time. I'm turning the call over to Max Gtaa A Precision A Q.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.